Canaccord analyst Susan Anderson lowered the firm’s price target on Prestige Consumer (PBH) to $88 from $100 and keeps a Buy rating on the shares. The firm said they posted solid results and management noted that sales and earnings exceeded expectations due to Clear Eyes supply timing and the timing of certain retailer orders, though this will come out of 3Q now.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer Healthcare Reports Q2 Fiscal 2026 Results
- Prestige Consumer Healthcare’s Earnings Call Highlights Growth and Challenges
- Strong Performance and Positive Outlook: Buy Rating for Prestige Consumer Healthcare
- Prestige Consumer narrows FY26 adj EPS view to $4.54-$4.58 from $4.50-$4.58
- Prestige Consumer reports Q2 adjusted EPS $1.07, consensus 97c